🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — March 13, 2026

Across 41 8-K filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive financing maneuvers (e.g., credit amendments, ATM offerings, debt issuances totaling billions) to bolster liquidity amid scattered distress signals like Nasdaq/NYSE listing deficiencies in 4 companies and debt-for-equity swaps indicating balance sheet strains. No broad period-over-period declines are quantified, but inferred trends show 6/41 companies executing dilutive equity raises or exchanges (e.g., NextNRG's $1.75M debt-for-3.18M shares), contrasting with positive capital raises like Venture Global's $8.6B CP2 Phase 2 FID. Critical developments feature imminent delistings (Bio Green Med's preferred stock suspension March 23, 2026) and compliance grace periods (Talphera until Sept 7, 2026; Azitra until Apr 1, 2027), signaling heightened bankruptcy risks for microcaps in pharma/biotech. Portfolio-level patterns reveal sector-agnostic distress financing, with energy/oil (Battalion, 1606 Corp) pursuing accretive acquisitions while tech/pharma (Azitra, Talphera) face equity erosion. Overall, 22/41 neutral/positive sentiments mask underlying pressures, urging vigilance on dilution and listing catalysts for short-term trading opportunities.

41 high priority 41 total filings
· daily

US SEC Trading Suspension Halt Orders — March 13, 2026

Four small-cap companies across healthcare and biotech sectors reported critical US exchange listing compliance failures in March 2026, highlighting a portfolio-level trend of microcap distress with 3/4 filings showing negative sentiment and persistent financial weaknesses like low bid prices, equity deficiencies, and MVPHS shortfalls. No positive YoY/QoQ revenue or margin trends evident; instead, Azitra disclosed net losses across five consecutive fiscal years ended Dec 31, 2025, with stockholders' equity at $3.8M versus $6.0M required, signaling ongoing deterioration from prior $4.0M deficiency. Bio Green Med faces imminent preferred stock delisting and trading suspension on Mar 23, 2026, post-180-day compliance failure from Sep 11, 2025 notice, while Talphera's bid price < $1.00 for 30 days triggers 180-day clock to Sep 7, 2026. Sadot Group resolved a voting rights violation via amendment, marking the sole mixed-positive outcome. Market implications include elevated delisting risks, potential reverse splits, OTC migrations, and short-term price volatility, with no insider buying or dividend hikes to signal conviction—watch for cascading suspensions in weak microcaps.

4 high priority 4 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 13, 2026

Across 39 filings on USA Board Room Changes from March 13, 2026, a dominant theme is elevated C-suite and board turnover, with 12 CFO/EVP Finance-related changes (resignations in Sprout Social, Waste Management, Wheeler REIT; appointments in CONMED, Hexcel, Orgenesis, Mitesco) signaling potential execution risks amid interim leadership in multiple firms. Director resignations/retirements affected 14 companies (e.g., Nine Energy, Vitesse, Six Flags, Goldman Sachs), often voluntary or age-related, balanced by 10 new appointments of experienced executives/directors (e.g., Avidbank, Hexcel CFO from Axcelis, Cyber App Solutions). Equity incentives surged as retention tools, with grants/RSUs/DCAs in 11 firms (Forward Industries options, Adient $500k RSU, Paymentus RSUs, Optimum $9.375M DCAs), reflecting alignment but mixed AGM votes (Veru 975k against equity plan, F5 16.1M against incentives). No broad YoY/QoQ financial declines noted, but Vitesse's 67% 2026 oil production hedged at $64-67/Bbl supports dividends positively; capital allocation leans toward reinvestment via incentives over buybacks/dividends. Portfolio-level pattern: Higher materiality (7-8/10) events cluster in tech/SaaS (Sprout, Asana) and finance (Waste Mgmt, Avidbank), implying sector-specific leadership refreshes for growth/turnarounds. Market implications: Bullish for firms with proven hires, bearish for abrupt exits without successors, creating near-term volatility opportunities.

39 high priority 39 total filings
· daily

US Merger & Acquisition SEC Filings — March 13, 2026

The 13 filings reveal a surge in SPAC activity with 7/13 involving blank check companies, including 3 IPOs/pricings (Kensington $230M, SUMA $150M) and extensions/deposit (Inception $12k for 1-month to April 13), signaling robust capital raising for M&A amid a 24-36 month combination windows. M&A completions dominate with IF Bancorp merger finalized at $26.40/share cash (delisting March 13), Aditxt's $36M oncology acquisition, and asset sales like Kaanapali's $19.9M land ($10.3M gain) and Moody REIT's $18.85M hotel disposition, though pro forma sales declines noted in 2 cases. Mixed sentiment in 3 filings highlights pro forma deteriorations (New Mountain net assets -3% to $1.153B, realized losses widened to $155M), but overall positive tone in 6/13 with no YoY/QoQ revenue declines beyond isolated pro formas (-$123k 2024 sales for Kaanapali). No insider trading or capital allocation shifts reported across filings, but forward-looking catalysts cluster in March (delistings, trading starts, closings). Portfolio-level trend: Elevated M&A velocity in SPACs/tech/healthcare vs quieter real estate dispositions; implications include heightened takeover premiums and de-SPAC opportunities, with $230M+ trust accounts positioning energy/tech targets.

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 13, 2026

Overnight SEC filings for March 13, 2026, reveal a mix of FY2025 10-K annual reports dominating (e.g., banks, pharma, REITs, BDCs), with period-over-period trends showing resilient revenue growth in select pharma/biotech (avg +25% YoY for Tonix, SenesTech, Vaxart) and banks (Red River net income +25% YoY, First Northern NII +4.8%), but widespread margin pressures and operating losses in industrials/REITs (Quest revenue -13% YoY, BRT NOI flat). Capital allocation leans positive with buybacks (News Corp $1B program, First Northern 1M+ shares authorized), dividends (BRT AFFO +3%), and financings (Karman +$100M revolver, Olenox $810k preferred). Auditor changes (Amplify material weakness) and litigation (Scilex fraud suit) flag risks, while M&A/acquisitions (Battalion 7k acres all-stock) and guidance (Emerald FY26 revenue $490-495M) offer catalysts. Sector themes include banking NIM expansion (Red River +14 bps to 3.38%) vs deposit declines, BDC portfolio ramps (Unknown Co net assets +huge from inception), and mixed pharma commercialization ramps amid high cash burn. Portfolio-level: 12/20 10-Ks mixed sentiment, cash positions strengthened in 8/15 reporting cos (e.g., Tonix to $207M), signaling near-term runway but watch for Q1 2026 guidance shifts. Actionable: Favor banks/BDCs with NIM/ROE gains, avoid litigation-exposed biotech.

35 high priority 15 medium 50 total filings
· daily

DHS Homeland Security Contracts — March 12, 2026

DHS awarded $263.5M in contracts over this period, with all three signaling bullish momentum for border security and infrastructure, including $177M tied to CBP priorities. Leidos shows execution strength with $74M (82%) outlayed on border detection tech, while RQ-AECOM and MARCOM offer full-value upside despite $0 outlay. Cross-cutting firm fixed price structures (two contracts) highlight revenue visibility amid execution risks, prioritizing contractors in hazard detection, construction, and recruitment.

3 total filings
· daily

VA Healthcare & Services Contracts — March 12, 2026

Oracle Health Government Services holds $245M in committed VA EHRM deployment contracts (Waves F&G), non-competitive awards signaling dominant federal health IT position with performance ending April 2026. Zero outlay across both despite 4-5 year terms introduces near-term revenue recognition upside but cash flow timing risks. Bullish backlog supports Oracle's government services growth amid VA modernization.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — March 12, 2026

Two firm fixed price contracts totaling $178.7M signal strong federal demand for NAICS 236220 commercial building construction, with BL Harbert ($92.5M DOJ dorm renovation) and RQ-AECOM JV ($86.3M DHS Coast Guard rebuild) gaining multi-year revenue through 2026-2028. Significant subcontracting ($29M and $102M respectively) highlights execution dependencies but provides revenue visibility amid full/open competition. Investors in federal construction should overweight bullish signals while monitoring FFP cost risks and outlay progress.

2 total filings
· daily

Federal Professional Services Contracts — March 12, 2026

Miracle Systems LLC, a small disadvantaged business, captured a $224M GSA delivery order for CISA Program Management Support Services under full and open competition, delivering a strong bullish signal with upside to $271M including options. No funds outlayed yet delays revenue but exposes medium-term growth via options and potential extensions through 2026. This sole record highlights SDB competitiveness in federal engineering services amid cybersecurity priorities.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — March 12, 2026

Aggregate $520M in federal IT contracts dominated by Oracle's $245M (47%) VA EHRM deployments, signaling strong healthcare IT modernization demand with bullish revenue visibility into 2026. Booz Allen's $90M FBI win (53% outlayed) adds momentum in justice IT, while GAMA-1 shows NOAA cloud progress (60% outlayed). Options offer $400M+ upside, but zero outlays in three contracts flag near-term cash flow risks.

5 total filings
· daily

New Federal Contractors — March 12, 2026

This $3.98B batch of 14 new federal contracts signals strong bullish momentum for U.S. government contractors, particularly in IT services ($1.1B+ across VA EHRM, CISA, NOAA, FBI, FAA) and construction/remediation ($1.9B including DOE Hanford cleanup and DHS/Coast Guard projects), with 11/14 rated bullish. Oracle Health stands out with $245M in VA EHRM deployments through 2026, while long performance periods (mostly to 2026-2028) provide multi-year revenue visibility despite $0 outlay on 6 contracts signaling delayed cash flows. Neutral signals limited to nonprofits and small private firms limit equity upside there.

14 total filings
· daily

Significant Contract Modifications ($10M+) — March 12, 2026

This $3.98B batch of significant contract modifications signals robust federal spending on IT modernization, border security, environmental cleanup, and healthcare outreach, with 11/14 bullish for key contractors like Oracle ($245M VA EHRM), Leidos ($91M CBP), and Central Plateau Cleanup ($1.7B DOE Hanford). Long performance periods to 2028+ provide multi-year revenue visibility but carry execution risks from zero outlays in 6 contracts and heavy subawarding. Institutional investors should prioritize public firms (Oracle, Leidos, Booz Allen, IBM) for near-term upside from unexercised options totaling >$500M across portfolio.

14 total filings
· daily

Contract Deobligations Alert — March 12, 2026

This $3.98B batch of 14 contract deobligations is dominated by a $1.7B DOE Hanford cleanup award to Central Plateau Cleanup Co., signaling sustained federal remediation spending; IT modernization contracts for Oracle (VA EHRM, $245M combined), Leidos (DHS, $91M), and Booz Allen (DOJ, $90M) highlight multi-year revenue in healthcare and homeland security IT. Eleven bullish signals outweigh 3 neutrals (nonprofits/small biz), with unexercised options exceeding $800M across deals providing upside; however, 6 contracts show $0 outlays despite multi-year histories, flagging execution delays. Investors should prioritize public federal IT/contractors amid 2026-2033 performance tails.

14 total filings
· daily

Contract Option Exercises — March 12, 2026

Contract option exercises totaling $3.98B signal strong federal spending continuity, dominated by $1.7B DOE Hanford cleanup (Central Plateau) and $817M HHS health exchange outreach (IPG Dxtra), with 11/14 bullish on IT services and construction firms. Multi-year commitments through 2028+ provide revenue visibility for public players like Oracle ($245M VA EHRM), Leidos ($91M DHS), and Booz Allen ($90M DOJ IT), amid zero-outlay delays in 6 contracts. Risks from FFP overruns and T&M audits are offset by $500M+ in unexercised options across deals.

14 total filings
· daily

All HHS Contracts — March 12, 2026

A single massive $817M HHS delivery order to IPG DXTRA, INC. highlights robust federal demand for health insurance exchange outreach via advertising, with $770M already outlayed providing immediate revenue visibility through 2027. This Time & Materials contract under full competition signals strength in government comms services, though long duration exposes to fiscal risks. Investors gain a high-confidence bullish entry on IPG DXTRA and NAICS 541810 peers amid concentrated HHS spending.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — March 12, 2026

Six mega contracts totaling $3.26B signal strong federal spending commitments through 2027, with 5 bullish signals dominated by IT services (Oracle's $245M VA EHRM duo) and remediation services. Unexercised options exceed $167M across contracts, offering upside, while $0 outlays on three awards ($469M total) flag near-term revenue delays. Neutral nonprofit funding to AIT underscores stable but non-equity yielding flows in international affairs.

6 total filings
· daily

High-Value Federal Grants ($5M+) — March 12, 2026

This $3.98B batch of 14 high-value federal contracts (>$5M) signals strong bullish momentum for government contractors in IT modernization, construction, and remediation, with 11/14 rated bullish and total obligations skewed toward DOE ($1.7B Hanford cleanup) and HHS ($817M health exchange outreach). Multi-year performance periods (avg. to 2026-2028) provide revenue visibility, but zero outlays in 6 contracts flag near-term cash flow delays. Institutional investors should prioritize public govcon equities like Oracle, Leidos, and Booz Allen for EHRM, border tech, and FBI IT exposure, while monitoring unexercised options totaling >$700M across deals.

14 total filings
· daily

DOE Energy Grants — March 12, 2026

DOE awarded Central Plateau Cleanup Company a $1.7B cost-plus incentive fee contract for Hanford Central Plateau remediation, with $1.63B outlayed on a 2021-2024 performance period, signaling robust federal spending on nuclear waste management. Unexercised options worth $65.6M and anticipated post-2024 needs offer revenue upside, though execution hinges on 141 subawards totaling $45M. This single large obligation highlights concentration risk in DOE cleanup funding for NAICS 562910 remediation services.

1 total filings
· daily

General Federal Contracts — March 12, 2026

This $3.98B batch of 14 federal contracts shows overwhelming bullish signals (11/14), concentrated in IT services ($1.1B+ across VA Oracle duo, Booz Allen, IBM, others) and construction ($265M+), signaling sustained federal spending on EHR modernization, border enforcement, and infrastructure despite zero outlays in 6 contracts. DOE's $1.7B Hanford cleanup and HHS's $817M health outreach anchor mega-revenue streams through 2027, with DHS (4 contracts, $344M) highlighting border/homeland priorities. Investors should prioritize public IT/construction giants like Oracle and Leidos for revenue visibility, monitoring option exercises ($500M+ potential) amid FFP/T&M execution risks.

14 total filings